GH Research (GHRS) Cash from Investing Activities (2021 - 2025)

GH Research's (GHRS) quarterly Cash from Investing Activities came in at $8.8 million in Q4 2025, down 58.56% year-on-year from $21.3 million in Q4 2024, and down 9.65% quarter-over-quarter from $9.8 million in Q3 2025.

GH Research (GHRS) Cash from Investing Activities (2021 - 2025) Analysis & Trends

GH Research's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at $8.8 million for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 58.56% year-over-year to $8.8 million in Q4 2025; TTM through Dec 2025 was $46.2 million, a 29.11% decrease from a year earlier, with the FY2025 full-year figure at $46.2 million, down 29.11% from the prior year.
  • Cash from Investing Activities eased to $8.8 million in Q4 2025 per GHRS's latest filing, from $9.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $21.3 million in Q4 2024 and bottomed at -$84.6 million in Q4 2022.
  • The 5-year median for Cash from Investing Activities is -$12000.0 (2021), against an average of -$1.4 million.
  • Across the five-year window, Cash from Investing Activities tumbled 540120.0% in 2023 and soared 191150.0% in 2024, its largest moves.
  • Year by year, Cash from Investing Activities stood at -$19000.0 in 2021, then plunged by 445368.42% to -$84.6 million in 2022, then jumped by 99.97% to -$24000.0 in 2023, then jumped by 88979.17% to $21.3 million in 2024, then slumped by 58.56% to $8.8 million in 2025.
  • Per Business Quant, the three latest GHRS Cash from Investing Activities figures stand at $8.8 million (Q4 2025), $9.8 million (Q3 2025), and $15.7 million (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 172.62 Mn
10 GH Research 1.65 Bn 1.65 Bn - 8.84 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 8.84 Mn
Dec 31, 2025 8.84 Mn
Sep 30, 2025 9.78 Mn
Sep 30, 2025 9.78 Mn
Jun 30, 2025 15.71 Mn
Jun 30, 2025 15.71 Mn
Mar 31, 2025 11.84 Mn
Mar 31, 2025 11.84 Mn
Dec 31, 2024 21.33 Mn
Dec 31, 2024 21.33 Mn
Sep 30, 2024 15.28 Mn
Sep 30, 2024 15.28 Mn
Jun 30, 2024 19.73 Mn
Jun 30, 2024 19.73 Mn
Mar 31, 2024 8.79 Mn
Mar 31, 2024 8.79 Mn
Dec 31, 2023 -24,000.00
Dec 31, 2023 -24,000.00
Sep 30, 2023 -8,000.00
Sep 30, 2023 -8,000.00